- Home
- REBN vs CANF Comparison
REBN vs CANF Comparison
Compare REBN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- CANF
- Stock Information
- Founded
- REBN 2015
- CANF 1994
- Country
- REBN United States
- CANF Israel
- Employees
- REBN N/A
- CANF N/A
- Industry
- REBN Restaurants
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- CANF Health Care
- Exchange
- REBN Nasdaq
- CANF Nasdaq
- Market Cap
- REBN 13.5M
- CANF 14.8M
- IPO Year
- REBN 2022
- CANF N/A
- Fundamental
- Price
- REBN $2.88
- CANF $1.05
- Analyst Decision
- REBN
- CANF Strong Buy
- Analyst Count
- REBN 0
- CANF 2
- Target Price
- REBN N/A
- CANF $14.00
- AVG Volume (30 Days)
- REBN 97.6K
- CANF 172.6K
- Earning Date
- REBN 03-31-2025
- CANF 05-27-2025
- Dividend Yield
- REBN N/A
- CANF N/A
- EPS Growth
- REBN N/A
- CANF N/A
- EPS
- REBN N/A
- CANF N/A
- Revenue
- REBN $5,928,533.00
- CANF $674,000.00
- Revenue This Year
- REBN $335.98
- CANF $461.72
- Revenue Next Year
- REBN N/A
- CANF N/A
- P/E Ratio
- REBN N/A
- CANF N/A
- Revenue Growth
- REBN 7.63
- CANF N/A
- 52 Week Low
- REBN $1.03
- CANF $1.02
- 52 Week High
- REBN $8.80
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- REBN 47.87
- CANF 37.30
- Support Level
- REBN $2.46
- CANF $0.98
- Resistance Level
- REBN $3.45
- CANF $1.14
- Average True Range (ATR)
- REBN 0.23
- CANF 0.06
- MACD
- REBN 0.08
- CANF 0.01
- Stochastic Oscillator
- REBN 45.19
- CANF 32.59
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).